Imsidolimab HARP Phase 2 fails to beat placebo in hidradenitis suppurativa; HS development halted

ANAPTYSBIO, INC

Imsidolimab did not improve primary endpoint (AN count change) or HiSCR50 vs placebo at Week 16 in moderate-to-severe HS.
No imsidolimab-related serious/severe AEs; safety profile acceptable across arms.
Company discontinues imsidolimab development in HS; GEMINI-1 Phase 3 for GPP continues with data expected Q4 2023.
Plans to outlicense imsidolimab prior to potential FDA approval for GPP; focus on rosnilimab and ANB032 immune cell modulators.
Cash over $570M at Q2 end; AZURE Phase 2 rosnilimab data in alopecia areata anticipated Q1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.